News

UCB has completed its acquisition of Ra Pharmaceuticals, priced at about $2.3 billion, meaning that zilucoplan — an investigational treatment for myasthenia gravis (MG) — is being added to UCB’s product pipeline. The transaction, whose start was announced by UCB last year, is expected to…

Cell models that best mirror the surface of muscle cells crowded with acetylcholine receptors (AChR) are most helpful for understanding how self-reacting antibodies interrupt communication between nerve cells and muscles in myasthenia gravis (MG), a study reports. Using these models, researchers found that some antibodies only recognize clustered receptors,…

Treatment with Soliris (eculizumab) leads to significant benefits in people with treatment-resistant generalized myasthenia gravis (gMG), including those with myasthenic crisis and thymoma-associated disease, a real-world study from Japan shows. The data suggest that Soliris may be suitable for gMG patients with these features and who also check predefined…

First, the bad news: If you’re one of the 30 million or so Americans with a rare disease, you probably have lower immunity to the novel coronavirus than most people. Now, the good news: You already know how to face loneliness and adversity — qualities that make you far stronger…

Younger age, more advanced thymoma (tumors of the thymus) and cancer recurrence predict poorer survival in people with myasthenia gravis (MG) whose tumors are surgically removed, a large study from China reports. Older age, in contrast, seems to protect against the likelihood of a tumor returning. The study,…

The Living Rare, Living Stronger Patient and Family Forum, originally set for May 14–16 in Cleveland, Ohio, has been postponed until July 18–20 because of the coronavirus disease COVID-19 pandemic. The event’s sponsor, the National Organization for Rare Disorders (NORD),…

Even with the coronavirus pandemic ravaging Europe and much of the world, patient advocate Lucia Monaco, PhD, of Italy remains confident that the Paris-based nonprofit she chairs will see the approval of 1,000 new rare disease therapies by 2027. That group, the International Rare Diseases Research Consortium (IRDiRC) — launched…

Intravenous immunoglobulin (IVIg) works to treat people with myasthenia gravis (MG) by increasing the numbers of regulatory immune cells that help to control autoimmune reactions in the bloodstream, an early study suggests. A subset of these cells containing the CTLA-4 protein appears to be particularly important, and may provide…

Aimovig (erenumab) and the investigational immune therapy subcutaneous immunoglobulin (SCIg) can safely be used simultaneously to treat migraines and myasthenia gravis, according to a recent case report. Both treatments were found to be effective at treating their individual conditions in the same patient and did not…

Out-of-pocket expenses for people in China who have myasthenia gravis  increased from 2013 to 2015, suggesting that current policies for medical insurance in China are inadequate for those living with the disease, a new study has found. The study, “Out-of-pocket expenses for myasthenia gravis patients in China:…